Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 4, 2014
Fourth quarter marks third consecutive quarter of improved performance.
-
Dec 17, 2013
Latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient care.
-
Dec 11, 2013
Represents important milestone toward making WATCHMAN device available to patients with atrial fibrillation.
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
Data presented at NANS 2013 show highly significant reduction in pain and high trial therapy success rate in the treatment of chronic pain.
-
Dec 6, 2013
Companies will collaborate to provide promotional support for stent system in U.S. hospitals
-
Nov 25, 2013Advanced Stent Technology to Launch Immediately in the United States
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
-
Nov 19, 2013Boston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable Microcatheter
Proprietary shaft design enables better control in hard-to-navigate vessels
-
Nov 19, 2013
First system to selectively stimulate targeted areas of the brain to manage symptoms of debilitating disease
-
Nov 15, 2013
Patients In Germany receive new transcatheter aortic valve implantation devices specially designed for total control and accurate deployment.
-
Nov 1, 2013
Advances Boston Scientific's ability to more comprehensively serve the rapidly expanding global EP market.
-
Oct 31, 2013
New data demonstrate successful deployment in all 120 patients with no severe paravalvular regurgitation at 30 days
-
Oct 28, 2013
REDUCE-HTN data presented today at TCT demonstrate excellent safety profile.
-
Oct 28, 2013
Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...
-
Oct 28, 2013
Transcatheter Aortic Valve Replacement (TAVR) device offers precise positioning and placement, offering physicians unprecedented control.
-
Oct 24, 2013
Jeffrey Capello to transition out of CFO role at year-end
-
Oct 24, 2013
"We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation,” said CEO Mike Mahoney.
Oct 23, 2013Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbations
-
Oct 23, 2013
Award recognizes innovative S-ICD® System, the world's first and only subcutaneous implantable defibrillator.
-
Oct 9, 2013
MAJESTIC trial to study self-expanding DES System designed to treat superficial femoral artery (SFA) lesions.
-
Oct 8, 2013
University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity.
-
Oct 8, 2013Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session
Re-ROUTE trial data presented at VIVA 2013 late-breaking session
-
Sep 17, 2013
Reinforcing company's ongoing commitment to leadership in the global medical technology market.
Sep 17, 2013REPRISE II data honored as Best Abstract 2013 at PCR London valves course
Sep 12, 2013Represents significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System.
Sep 4, 2013Unlike medications alone, bronchial thermoplasty provides benefits that last for years rather than hours